AKBA
Akebia Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website akebia.com
- Employees(FY) 204
- ISIN US00972D1054
Performance
-13.53%
1W
-17.86%
1M
-20.69%
3M
+16.29%
6M
-7.26%
YTD
+1.77%
1Y
Profile
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Technical Analysis of AKBA 2024-05-10
Overview:
In analyzing the technical indicators for AKBA over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day Moving Average (MA) has been fluctuating around the c...
Recent News & Updates
- 2024-05-13 20:00
- 2024-05-10 03:27
- 2024-05-10 03:06
- 2024-05-08 23:57
- 2024-05-08 20:10
- 2024-05-08 20:10
- 2024-05-08 19:09
Akebia Therapeutics: Q1 Earnings Snapshot(Yahoo Finance)
- 2024-05-08 19:00
- 2024-05-01 20:30
- 2024-05-01 04:05
- 2024-04-02 04:05
- 2024-03-28 07:06
- 2024-03-27 23:50
- 2024-03-27 20:26
- 2024-03-27 19:06
- 2024-03-27 08:26
- 2024-03-26 01:12
Akebia Awaits FDA Word On Second Crack At Vadadustat(Yahoo Finance)
- 2024-03-17 09:25
- 2024-03-16 09:22
Akebia Therapeutics Full Year 2023 Earnings: EPS Beats Expectations(Simply Wall St.)
- 2024-03-14 17:30
- 2024-03-14 16:15
- 2024-03-14 09:53
- 2024-03-14 05:51
- 2024-03-14 05:30
- 2024-03-14 04:15
- 2024-03-11 17:05
- 2024-03-11 05:05
- 2024-03-01 16:05
- 2024-03-01 03:05
- 2024-02-02 03:05
Page 1 of 5
previousnext